Aktiverede T-celler i tumorer dræber andre cancerceller
Interessant studie hvor forskere fra Stanford University School of Medicine forsøger at injicere to immunstimulerende stoffer i tumorer på mus, hvorefter der elimineres kræft i kroppen selv andre steder i kroppen end tumoren. Der aktiveres T-celler i tumoren og nogle af dem forlader tumoren og går på jagt efter andre cancerceller i kroppen og dræber dem. I dette forsøg fik 87 ud af 90 mus kureret deres kræft.
Cancer ‘vaccine’ eliminates tumors in mice Activating T cells in tumors eliminated even distant metastases in mice, Stanford researchers found. Lymphoma patients are being recruited to test the technique in a clinical trial. Stanford Medicine 31. januar 2018
Selve studiet kan findes her:
Abstract It has recently become apparent that the immune system can cure cancer. In some of these strategies, the antigen targets are preidentified and therapies are custom-made against these targets. In others, antibodies are used to remove the brakes of the immune system, allowing preexisting T cells to attack cancer cells. We have used another noncustomized approach called in situ vaccination. Immunoenhancing agents are injected locally into one site of tumor, thereby triggering a T cell immune response locally that then attacks cancer throughout the body. We have used a screening strategy in which the same syngeneic tumor is implanted at two separate sites in the body. One tumor is then injected with the test agents, and the resulting immune response is detected by the regression of the distant, untreated tumor. Using this assay, the combination of unmethylated CG–enriched oligodeoxynucleotide (CpG)—a Toll-like receptor 9 (TLR9) ligand—and anti-OX40 antibody provided the most impressive results. TLRs are components of the innate immune system that recognize molecular patterns on pathogens. Low doses of CpG injected into a tumor induce the expression of OX40 on CD4+ T cells in the microenvironment in mouse or human tumors. An agonistic anti-OX40 antibody can then trigger a T cell immune response, which is specific to the antigens of the injected tumor. Remarkably, this combination of a TLR ligand and an anti-OX40 antibody can cure multiple types of cancer and prevent spontaneous genetically driven cancers. Science Translational Medicine 31 Jan 2018